Grand Rounds – Mass General Brigham Ventures: Investing in your Home-Grown Innovations | Meredith Fisher, PhD | July 20, 2022

Accelerating bench-to bedside innovations to the market is a process that can often be opaque challenging, and with various levels of success. It is crucial to have sufficient funding and effective partners to help you spin-out, validate, and scale your idea with the ultimate goal of positively impacting patient care.

Mass General Brigham Ventures invests exclusively in healthcare sector companies based on intellectual property created within our own research community. Initial investments are directed at the seed and Series A stages, where their participation attracts capital and talent into the most difficult-to-fund phase of company development. Our hospitals boast a history of medical firsts, including the use of TNF fusion protein for the treatment of rheumatoid arthritis (Enbrel®); elucidation of PD-1 receptor biology that spawned the field of immuno-oncology therapy; the discovery of CRISPR gene-editing technology; and the targeting of EGFR gene mutations that enable high-efficacy personalized lung cancer therapy. ​

Please join us to hear from Meredith Fisher, PhD, Partner at Mass General Brigham Ventures on strategies for early-stage investments and company creation surrounding your innovations. Previously, she was in the private/family office at Bracebridge Capital serving as Director of Private Investments where she led investments in early-stage life science companies. Prior to that role, she led business development for Ginkgo BioWorks and was Senior Director at PureTech Ventures. She spent several years working as a scientist in anti-viral drug discovery for Idenix Pharmaceuticals and Anadys Pharmaceuticals.

Learn More: www.innovationmeshnetwork.org / innovation.massgeneralbrigham.org

Chief Innovation Officer: Chris Coburn
Grand Rounds Director: Marc Succi, MD